CHILDREN and young adults with behavioural problems can hopefully look forward to a side effect-free cure. Britain's Medeva. a pharmaceuticals company and Chirosclence. a biotechnology < oncern. have come together to develop a purified version of Methylephenidate, a behaviour-

controlling drug, to control attention deficit disorder. Chirosclence uses chiral technology to develop purer forms of drugs, eliminating side effects. Methylphenidate accounts for about 27 per cent of Medeva's sales, mainly from highly controlled US market.

CSE/Down To Earth